KR20220025196A - 아달리무맙의 안정한 수성 제형 - Google Patents

아달리무맙의 안정한 수성 제형 Download PDF

Info

Publication number
KR20220025196A
KR20220025196A KR1020227004460A KR20227004460A KR20220025196A KR 20220025196 A KR20220025196 A KR 20220025196A KR 1020227004460 A KR1020227004460 A KR 1020227004460A KR 20227004460 A KR20227004460 A KR 20227004460A KR 20220025196 A KR20220025196 A KR 20220025196A
Authority
KR
South Korea
Prior art keywords
formulation
composition
adalimumab
buffer
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227004460A
Other languages
English (en)
Korean (ko)
Inventor
마크 매닝
로버트 더블유. 페인
Original Assignee
코히러스 바이오사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220025196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 코히러스 바이오사이언시즈, 인코포레이티드 filed Critical 코히러스 바이오사이언시즈, 인코포레이티드
Publication of KR20220025196A publication Critical patent/KR20220025196A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
KR1020227004460A 2012-09-07 2013-09-06 아달리무맙의 안정한 수성 제형 Ceased KR20220025196A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261698138P 2012-09-07 2012-09-07
US61/698,138 2012-09-07
US201361769581P 2013-02-26 2013-02-26
US61/769,581 2013-02-26
US201361770421P 2013-02-28 2013-02-28
US61/770,421 2013-02-28
PCT/US2013/058618 WO2014039903A2 (en) 2012-09-07 2013-09-06 Stable aqueous formulations of adalimumab
KR1020217010005A KR102362829B1 (ko) 2012-09-07 2013-09-06 아달리무맙의 안정한 수성 제형

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010005A Division KR102362829B1 (ko) 2012-09-07 2013-09-06 아달리무맙의 안정한 수성 제형

Publications (1)

Publication Number Publication Date
KR20220025196A true KR20220025196A (ko) 2022-03-03

Family

ID=50237778

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227004460A Ceased KR20220025196A (ko) 2012-09-07 2013-09-06 아달리무맙의 안정한 수성 제형
KR1020157008873A Expired - Fee Related KR102238677B1 (ko) 2012-09-07 2013-09-06 아달리무맙의 안정한 수성 제형
KR1020217010005A Expired - Fee Related KR102362829B1 (ko) 2012-09-07 2013-09-06 아달리무맙의 안정한 수성 제형

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157008873A Expired - Fee Related KR102238677B1 (ko) 2012-09-07 2013-09-06 아달리무맙의 안정한 수성 제형
KR1020217010005A Expired - Fee Related KR102362829B1 (ko) 2012-09-07 2013-09-06 아달리무맙의 안정한 수성 제형

Country Status (31)

Country Link
US (39) US20140186361A1 (https=)
EP (2) EP2892550B1 (https=)
JP (3) JP6463268B2 (https=)
KR (3) KR20220025196A (https=)
CN (1) CN104768576A (https=)
AR (1) AR092470A1 (https=)
AU (3) AU2013312300A1 (https=)
BR (1) BR112015004984A2 (https=)
CA (2) CA3153799A1 (https=)
CL (1) CL2015000574A1 (https=)
CY (1) CY1123407T1 (https=)
DK (1) DK2892550T3 (https=)
DO (1) DOP2015000051A (https=)
EA (2) EA029215B1 (https=)
EC (1) ECSP15013227A (https=)
ES (1) ES2784861T3 (https=)
HR (1) HRP20200434T1 (https=)
HU (1) HUE049282T2 (https=)
IL (2) IL237583B (https=)
LT (1) LT2892550T (https=)
MX (1) MX2015003007A (https=)
PE (2) PE20150964A1 (https=)
PL (1) PL2892550T3 (https=)
PT (1) PT2892550T (https=)
RS (1) RS60226B1 (https=)
SG (2) SG10201705668XA (https=)
SI (1) SI2892550T1 (https=)
SM (1) SMT202000147T1 (https=)
TW (2) TWI698253B (https=)
UY (1) UY35351A (https=)
WO (1) WO2014039903A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP2015509526A (ja) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PE20150964A1 (es) * 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
BR112015017619A2 (pt) * 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd formulação líquida, uso de uma formulação, e, kit
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015151115A1 (en) 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
EP2946767B1 (en) * 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
PT2946765T (pt) * 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
KR20170018810A (ko) 2014-06-10 2017-02-20 메이지 세이카 파루마 가부시키가이샤 안정한 아달리무맙 수성 제제
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
US20180016333A1 (en) * 2015-01-28 2018-01-18 Mabxience, S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
SG11201706505PA (en) * 2015-02-13 2017-09-28 Sanofi Sa Stable liquid formulation for monoclonal antibodies
WO2016162819A1 (en) 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use
CN108778261A (zh) * 2016-01-12 2018-11-09 雷迪博士实验室有限公司 稳定的药物组合物
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
CN108718522A (zh) * 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
US20180043020A1 (en) * 2016-04-20 2018-02-15 Coherus Biosciences, Inc. Method of reducing immunogenicity of drug products
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
EP3479819B1 (en) 2016-06-30 2024-01-24 Celltrion Inc. Stable liquid pharmaceutical preparation
WO2018080196A2 (ko) * 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
MY197202A (en) * 2017-03-16 2023-05-31 Lg Chemical Ltd A liquid formulation of anti-tnf alpha antibody
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184693A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
CA3073935A1 (en) * 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
JP7820910B2 (ja) 2017-09-20 2026-02-26 アルヴォテック エイチエフ アダリムマブ用医薬製剤
JP7797098B2 (ja) 2018-03-29 2026-01-13 エアウェイ・セラピューティクス・インコーポレイテッド サーファクタントタンパク質ｄ（ｓｐ－ｄ）を含む方法及び組成物
KR20210102954A (ko) * 2019-01-11 2021-08-20 삼성바이오에피스 주식회사 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도
CN120241997A (zh) * 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
CN113727730A (zh) * 2019-03-18 2021-11-30 阿尔沃科技Hf公司 高浓度TNFα抗体的含水制剂
EP4021497B1 (en) * 2019-08-30 2026-02-25 Kashiv Biosciences, LLC Novel formulation of highly concentrated pharmacologically active antibody
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
BR112022013730A2 (pt) * 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
EP4108258A4 (en) * 2020-02-20 2024-03-06 Bio-Thera Solutions, Ltd. PREPARATION OF ANTI-TNF-ALPHA ANTIBODY, METHOD OF PREPARATION AND USE THEREOF
EP4119161A4 (en) * 2020-03-13 2024-05-15 Samsung Bioepis Co., Ltd. Liquid pharmaceutical composition having improved stability
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
US20230158143A1 (en) * 2020-05-21 2023-05-25 Shilpa Medicare Ltd Pharmaceutical compositions comprising adalimumab
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
CN116963775A (zh) * 2021-03-03 2023-10-27 爱乐科斯公司 抗siglec-8抗体制剂
EP4398932A4 (en) * 2021-09-07 2025-10-22 Dr Reddys Laboratories Ltd FORMULATIONS OF IMMUNE CHECKPOINT INHIBITORS OR ANALOGUES
EP4400116A4 (en) * 2021-09-16 2025-09-24 Aprogen Inc PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI-TNF ALPHA ANTIBODY
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂
WO2023183898A1 (en) * 2022-03-24 2023-09-28 Arch Oncology, Inc. Formulations for anti-cd47 antibodies
AU2024325145A1 (en) * 2023-08-15 2026-02-05 Amgen Inc. Acidic buffered intravenous solution stabilizers for use in methods of treatment

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
AU2989695A (en) 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6171576B1 (en) 1995-11-03 2001-01-09 Organix Inc. Dopamine transporter imaging agent
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
JP2000516594A (ja) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2635352C (en) * 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6171686B1 (en) 1997-10-03 2001-01-09 Marine Environmental Solutions, L.L.C. Synthetic aquatic structure
PT917879E (pt) 1997-11-22 2002-12-31 Roche Diagnostics Gmbh Processo melhorado para estabilizacao de proteinas
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
HUP0200575A3 (en) 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
CA2369444C (en) 1999-04-09 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical compositions of erythropoietin
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
WO2001047554A1 (fr) * 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
JP5490972B2 (ja) 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
EP1536835A1 (en) 2002-07-09 2005-06-08 Sandoz AG Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4500683B2 (ja) 2002-11-01 2010-07-14 バイエル・ヘルスケア・エルエルシー 巨大分子濃縮方法
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
EP1712240B1 (en) * 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
WO2006022599A1 (en) 2004-08-27 2006-03-02 Marian Metke Production method for exfoliated graphite, equipment for its production, exfoliated graphite and means of its use
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
KR101140483B1 (ko) 2007-05-02 2012-07-11 에프. 호프만-라 로슈 아게 단백질을 안정화시키는 방법
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
US20090151807A1 (en) 2007-08-07 2009-06-18 Davis Chanda Janese Container Insert for Zero Headspace
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
WO2009073805A2 (en) 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2711984A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
RU2011126338A (ru) 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
JP2012511531A (ja) 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2501408B1 (en) 2009-11-20 2020-05-27 Biocon Limited Formulations of antibody
BR112012013148A2 (pt) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
CN102946858B (zh) 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
FR2961107B1 (fr) 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
CH703405B1 (de) 2010-07-05 2014-05-15 Melexis Tessenderlo Nv Magnetischer Winkelsensor.
WO2012024650A2 (en) * 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US20120076779A1 (en) * 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
EP2699265B1 (en) 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
MX2013013437A (es) 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
WO2013096835A1 (en) 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
JP2015509526A (ja) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150102042A1 (en) 2012-07-10 2015-04-16 Gary Matsch Air Purging Lid
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
CN102988984B (zh) 2012-12-21 2015-05-20 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
CN105358042B (zh) 2013-05-13 2018-05-29 恩多巧爱思股份有限公司 内窥镜端头位置视觉指示器和热量管理系统
US9681695B2 (en) 2013-07-31 2017-06-20 Sport Maska Inc. Helmet with chin cup

Also Published As

Publication number Publication date
KR102362829B1 (ko) 2022-02-15
US20180311349A1 (en) 2018-11-01
US9340611B2 (en) 2016-05-17
US20180028654A1 (en) 2018-02-01
US10688183B2 (en) 2020-06-23
CY1123407T1 (el) 2021-12-31
US20150191539A1 (en) 2015-07-09
US20180028656A1 (en) 2018-02-01
US9757454B2 (en) 2017-09-12
US20180028653A1 (en) 2018-02-01
US20160256545A1 (en) 2016-09-08
JP2021020930A (ja) 2021-02-18
AU2013312300A1 (en) 2015-04-16
US9724414B2 (en) 2017-08-08
PE20191815A1 (es) 2019-12-27
ECSP15013227A (es) 2016-01-29
US10286071B2 (en) 2019-05-14
US10722579B2 (en) 2020-07-28
US10786566B2 (en) 2020-09-29
US20190070292A1 (en) 2019-03-07
US20190060455A1 (en) 2019-02-28
US10799585B2 (en) 2020-10-13
EA201791717A1 (ru) 2018-03-30
US20190070293A1 (en) 2019-03-07
US10207000B2 (en) 2019-02-19
IL237583A0 (en) 2015-04-30
US20160303235A1 (en) 2016-10-20
KR102238677B1 (ko) 2021-04-12
EA029215B1 (ru) 2018-02-28
US10195275B2 (en) 2019-02-05
US10716853B2 (en) 2020-07-21
US9782479B2 (en) 2017-10-10
CA2884182C (en) 2022-06-14
US20180043018A1 (en) 2018-02-15
US10159733B2 (en) 2018-12-25
US9770507B2 (en) 2017-09-26
EP2892550A4 (en) 2016-04-13
US20160304601A1 (en) 2016-10-20
US9861695B2 (en) 2018-01-09
TWI698253B (zh) 2020-07-11
IL277652A (en) 2020-11-30
US20180311351A1 (en) 2018-11-01
US9782480B2 (en) 2017-10-10
PE20150964A1 (es) 2015-07-25
US20180028657A1 (en) 2018-02-01
US10772960B2 (en) 2020-09-15
US20180140701A1 (en) 2018-05-24
US20170072054A1 (en) 2017-03-16
US20190070294A1 (en) 2019-03-07
CA3153799A1 (en) 2014-03-13
ES2784861T3 (es) 2020-10-01
IL277652B2 (en) 2023-04-01
US20160256546A1 (en) 2016-09-08
US20160303234A1 (en) 2016-10-20
HRP20200434T1 (hr) 2020-07-24
IL237583B (en) 2020-10-29
US9346880B2 (en) 2016-05-24
AR092470A1 (es) 2015-04-22
US20180055929A1 (en) 2018-03-01
US10155039B2 (en) 2018-12-18
US9731008B2 (en) 2017-08-15
HK1210601A1 (en) 2016-04-29
DK2892550T3 (da) 2020-03-30
CA2884182A1 (en) 2014-03-13
US9340612B2 (en) 2016-05-17
TW201424749A (zh) 2014-07-01
US20140186361A1 (en) 2014-07-03
US20180021433A1 (en) 2018-01-25
US20160031982A1 (en) 2016-02-04
US20180028655A1 (en) 2018-02-01
HUE049282T2 (hu) 2020-09-28
US9737600B2 (en) 2017-08-22
EP2892550B1 (en) 2019-12-18
AU2020202912A1 (en) 2020-05-21
EA201590518A1 (ru) 2016-05-31
US20170312361A1 (en) 2017-11-02
US10716852B2 (en) 2020-07-21
LT2892550T (lt) 2020-04-10
KR20210040470A (ko) 2021-04-13
US9682145B2 (en) 2017-06-20
JP2015527402A (ja) 2015-09-17
US10780163B2 (en) 2020-09-22
JP6783845B2 (ja) 2020-11-11
US20180311350A1 (en) 2018-11-01
WO2014039903A3 (en) 2014-06-26
US20160263226A1 (en) 2016-09-15
US20160304599A1 (en) 2016-10-20
US20160256547A1 (en) 2016-09-08
RS60226B1 (sr) 2020-06-30
UY35351A (es) 2014-08-29
US9731009B2 (en) 2017-08-15
US9789185B2 (en) 2017-10-17
EP3701968A1 (en) 2020-09-02
US20150191538A1 (en) 2015-07-09
SG11201501715QA (en) 2015-05-28
US20180043019A1 (en) 2018-02-15
AU2018208699A1 (en) 2018-08-16
US20150190513A1 (en) 2015-07-09
US20160039926A1 (en) 2016-02-11
CL2015000574A1 (es) 2015-10-23
US9808525B2 (en) 2017-11-07
US10159732B2 (en) 2018-12-25
WO2014039903A2 (en) 2014-03-13
MX2015003007A (es) 2015-06-05
US20160304600A1 (en) 2016-10-20
US20160303233A1 (en) 2016-10-20
US20180055930A1 (en) 2018-03-01
US20150190512A1 (en) 2015-07-09
JP6463268B2 (ja) 2019-01-30
EP2892550A2 (en) 2015-07-15
US10716854B2 (en) 2020-07-21
SG10201705668XA (en) 2017-08-30
US9724415B2 (en) 2017-08-08
US10286072B2 (en) 2019-05-14
KR20150047140A (ko) 2015-05-04
US9707293B2 (en) 2017-07-18
PT2892550T (pt) 2020-03-27
US20150182626A1 (en) 2015-07-02
JP2019069993A (ja) 2019-05-09
SMT202000147T1 (it) 2020-05-08
US10772959B2 (en) 2020-09-15
US20180311352A1 (en) 2018-11-01
US9382317B2 (en) 2016-07-05
DOP2015000051A (es) 2015-05-31
PL2892550T3 (pl) 2020-07-27
BR112015004984A2 (pt) 2017-07-04
CN104768576A (zh) 2015-07-08
SI2892550T1 (sl) 2020-11-30
TW202042841A (zh) 2020-12-01
IL277652B (en) 2022-09-01

Similar Documents

Publication Publication Date Title
KR102362829B1 (ko) 아달리무맙의 안정한 수성 제형

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220209

Application number text: 1020217010005

Filing date: 20210405

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220310

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220527

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220930

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220527

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I